Articles tagged with Lung Cancer
A University of Colorado Cancer Center study finds a genetic change called ALK-fusion in a patient sample of a melanoma subtype called mucosal melanoma. Treated with FDA-approved drugs, the tumor responded dramatically. The study suggests that these non-sun-exposed melanomas may be more susceptible to targeted treatments.
Gender disparities are identified in lung cancer screening and care, with more female patients meeting high-risk criteria but not completing low-dose CT scans. Language barriers do not delay initiation of lung cancer care, according to a second study.
A study published in The Lancet Public Health found that federal drinking water regulations reduced toxic exposure and protected human health. Compliance with the EPA regulation led to a decline of 17% in levels of urinary arsenic, resulting in an estimated reduction of over 200 cases of lung and bladder cancer every year.
The Terry Fox Research Institute study found that the Pan Can Lung Cancer Risk Prediction Model outperformed comparable models in detecting early-stage lung cancer. The model identified high-risk individuals and detected cancer early, saving lives.
A community-based intervention called c-CARE improved cancer literacy and reduced disparate lung cancer outcomes among minority communities. The study found that participants showed increased knowledge and self-efficacy for lung cancer screening, but not perceived susceptibility.
A 12-week physical and psycho-social intervention improved functional capacity in advanced lung cancer patients, while also enhancing their quality of life. The study's findings suggest that exercise interventions can be a beneficial approach for these patients, reducing the burden on caregivers and improving overall well-being.
A study integrating smoking cessation programs with low-dose CT lung cancer screenings found that this approach can decrease mortality rates while being relatively cost-effective. The research suggests that adding a robust smoking cessation intervention to an organized LDCT screening program could result in significantly fewer deaths, ...
Researchers found that treating stage II and III non-small cell lung cancer (NSCLC) patients with chemotherapy based on their specific BRCA1 expression levels did not increase overall survival rates. However, BRCA1 expression levels were found to be prognostic, and individualized treatment could achieve different outcomes.
A study published in the IASLC 18th World Conference on Lung Cancer found that early specialist palliative care for recently diagnosed malignant pleural mesothelioma (MPM) patients does not impact quality of life. Researchers concluded that there is no role for routine early referral to palliative care, regardless of symptoms.
A study analyzing over 1.1 million NSCLC cases found significant disparities in survival rates based on race and socioeconomic factors such as education level and income. Patients of Asian and Hispanic backgrounds had better overall survival rates compared to Whites and Blacks.
Researchers confirmed IASLC's proposed criteria for uncertain resection margin status (R(un)) have a prognostic value between R0 and R1. The study analyzed data from 14,712 patients and evaluated the impact of various factors on survival.
Researchers found that NatD promotes lung cancer progression by preventing histone H4 serine phosphorylation, leading to increased invasiveness and poor clinical outcomes. Depletion of NatD suppresses EMT via repression of Slug expression, suggesting a new therapeutic target for cancer treatment.
Dr. Yuze Sun is developing an optofluidic gas-analyzing microsystem to detect biomarkers in human exhaled breath for early stage lung cancer detection. The technology aims to replace invasive biopsies and needle pokes with a non-invasive screening method.
PharmaMar's Phase I/II trial combining PM1183 with doxorubicin shows a progression-free survival of 5.3 months, surpassing historical data for topotecan. The study also reveals manageable adverse events with no mucositis or neuropathy, paving the way for the pivotal Phase III Atlantis trial.
A DNA variant in the DNMT3B gene is associated with an increased risk of nicotine dependence, as well as heavier smoking and a higher likelihood of developing lung cancer. The study, which analyzed over 38,600 participants, provides new insights into the genetic factors influencing addiction.
Researchers at CRI discover lactate acts as a fuel source for growing tumors, contradicting the nearly century-old Warburg effect. The finding has significant implications for therapies and imaging techniques for lung cancer.
Anti-RAS antibodies are a critical research tool, but their poor reliability limits replicable study results. Researchers identified selectively recognizing each of the four human RAS proteins only in Western blot assays.
A laboratory-based study discovered that an alcohol aversion drug can reverse chemotherapy resistance in non-small cell lung cancer. The researchers found that the drug, Disulfiram, inhibited ALDH activity, reducing tumour cell growth and killing lung cancer stem cells.
A study found that mutations in the KEAP1 gene make lung adenocarcinoma cells vulnerable to oxidative stress, allowing an experimental drug called CB-839 to stop tumor growth. The discovery could lead to a more effective treatment for patients with combined KRAS and KEAP1 mutations.
Researchers used a proteomics platform to identify proteins with reactive cysteines in non-small-cell lung cancer cells, which could be targeted by drugs. The study found that targeting the protein NR0B1 reduced abnormal growth in NRF2-activated lung cancers.
A pilot program using big data predicts ED visits in lung cancer patients with 33% accuracy. The model identifies high-risk patients who are 6.6 times more likely to visit the ED compared to low-risk patients.
A phase III trial demonstrates a 32 percent overall survival rate at five years, setting a new benchmark for patients with inoperable stage III NSCLC. The trial also confirms that using a higher radiation dose is not beneficial and can lead to detrimental outcomes.
A recent study led by Massachusetts General Hospital estimates that nearly 10% of people with HIV currently in care in the US will die from lung cancer. Quitting smoking is crucial for reducing the risk of lung cancer and other diseases among people with HIV.
A new study projects increased lung cancer death risks among people living with HIV who smoke, with heavy smokers facing the highest mortality rates. The study suggests that tobacco use accelerates lung cancer development and should be prioritized in comprehensive care for HIV patients.
Researchers at Brigham and Women's Hospital discovered a rare genetic mutation in the ALK gene that causes peritoneal mesothelioma in young women with no history of asbestos or radiation therapy. Targeted therapy using FDA-approved drugs may be effective in treating these patients.
A study of British general practitioners found that physicians are more likely to support smoking cessation in primary care patients with coronary heart disease. Cancer patients are less likely to stop smoking due to lack of recording and advice from their doctors.
Researchers have identified a molecule called miR-124 in non-small cell lung cancer cells that plays a regulatory role in programmed cell death. The findings may offer a new target in the fight against non-small cell lung cancer, particularly for mesenchymal-like cells resistant to chemotherapy.
Researchers found that chronic cigarette smoke exposure leads to epigenetic changes in lung cells, silencing protective genes and priming them for cancer. These changes can be reversed by quitting smoking, suggesting a potential strategy for reducing lung cancer risk.
Scientists at Johns Hopkins Kimmel Cancer Center found that cigarette smoke triggers epigenetic changes in human airway cells, sensitizing them to genetic mutations. These changes precede and silence key tumor suppressor genes, leading to increased KRAS signaling and cancer development.
The PACIFIC trial showed that durvalumab improved progression-free survival in patients with locally advanced, unresectable stage II-III NSCLC, decreasing the probability of disease progression by 48%. Durvalumab also reduced treatment-related adverse events and improved overall response rates.
A study published at ESMO 2017 Congress found that abdominal fat distribution is a significant predictor of cancer diagnosis in postmenopausal women. The study, which included 5,855 women, showed that the ratio of abdominal to peripheral fat was an independent risk factor for certain cancers.
Researchers at the University of Southern Denmark have discovered a new strategy to overcome resistance in lung cancer, which often leads to treatment failure. By combining an EGFR tyrosine kinase inhibitor with an AKT inhibitor, tumor growth can be arrested, potentially improving patient survival.
A University of Colorado study found that blood tumor markers can predict lung cancer progression, allowing for earlier adjustments to treatment plans. Markers were associated with a 10% or greater rise in 53% of patients experiencing cancer progression, but not limited brain progression cases.
The study found that regular CT scans may not be necessary for follow-up, suggesting a conservative approach to monitoring the disease. The findings challenge standard clinical practice guidelines recommending chest CT scans every three to six months in the first two years after surgery.
Researchers developed a new assay to detect gene fusions in dozens of genes simultaneously, identifying a rare MET fusion in a late-stage lung cancer patient. The patient showed an almost complete response to targeted therapy crizotinib after over 8 months of treatment.
The largest study on hardmetal workers found no increased risk of lung cancer or death due to the substance's use in the industry. Short-term workers showed small excesses in lung cancer mortality, attributed to lifestyle and behavior factors rather than occupational exposure.
Researchers found that patients who received canakinumab had a marked reduction in lung cancer incidence and mortality, with death from cancer reduced by half in the highest dosage group. The study suggests that anti-inflammatory therapy may help slow lung cancer progression.
The CANTOS trial found that canakinumab significantly reduced the risk of cardiovascular events and total cancer death, with dose-dependent effects on lung cancer rates. The study showed a 15% reduction in cardiovascular event risk and a 17% reduction in hospitalization for unstable angina.
Long-term use of high-dose vitamin B6 and B12 supplements is associated with a two- to four-fold increased lung cancer risk in men. Male smokers taking these supplements were three times more likely to develop lung cancer, while those taking higher doses were approximately four times more likely.
Researchers at Norton Thoracic Institute have developed a new approach to treat an aggressive subgroup of lung cancer. The study found that patients with tumors harboring specific genomic mutations, such as KRAS and LKB1, are more likely to benefit from a novel drug in clinical trials.
Researchers have developed a novel blood biopsy test that reads platelets to detect human lung cancer with high accuracy. The thromboSeq test analyzes tumor RNA absorbed by circulating platelets and has shown promising results in diagnosing non-small cell lung cancer, achieving up to 90% accuracy.
Lung cancer clinical trials have complex requirements that act as a barrier to development and patient enrollment. A retrospective study found an increase in eligibility criteria for medical therapy trials, particularly for cardiac, concurrent medications, and immunotherapy-related treatments.
A study by the Lung Cancer Mutation Consortium identified HER2 mutations in 24 lung cancer patients (3%), with median survival doubling when treated with HER2-directed therapy. This finding suggests a significant population of HER2+ lung cancer patients, highlighting the need for targeted therapies.
A new study published in Thorax found that smokers who undergo a low-dose CT scan of their lungs are more likely to quit smoking. The UK Lung Cancer Screening trial involved 4,055 participants and showed a 15% success rate in quitting after two years.
The European Society for Medical Oncology has announced the recipients of its four distinguished annual awards. Miguel Martin is recognized for his work in breast cancer research, while José Baselga receives the Lifetime Achievement Award for pivotal contributions to drug development. Alberto Bardelli wins the Translational Research Aw...
A study by MD Anderson Cancer Center found improved survival rates for patients with stage 3 lung cancer treated with concurrent chemotherapy and proton therapy. The treatment reduced toxic effects compared to standard care, with a median overall survival of 26.5 months.
Researchers used mathematical modeling to examine patterns in lung cancer metastases, revealing a preferential pattern for brain spread in patients with EGFR mutations. The findings suggest that Markov modeling could help predict metastatic spread and personalize treatment for non-small cell lung cancer patients.
A new study has identified 18 genetic variations associated with lung cancer risk and 10 new gene variations. The research, conducted by an international team, used a special research platform called OncoArray to gather genotype data from different studies worldwide.
A new study indicates that Holocaust survivors have a small but consistent increase in cancer risk, linked to extreme population-level tragedies. Survivors exposed to starvation, overcrowding, and psychological stress had higher risks of developing certain types of cancer, including colorectal and lung cancers.
A new circular RNA marker has been identified in blood and lung tissue, associated with increased cell proliferation, migration, and invasion. High expression of this marker may improve lung cancer screening and detection at late stages.
A new report finds that nearly half of all cancer deaths in China are attributable to potentially modifiable risk factors. The study reveals that effective public health interventions can have a significant impact on reducing the cancer burden in China.
Researchers at Dartmouth Health have received a five-year, $12.1 million NIH grant to study and improve the precision of lung cancer risk and screening. The team aims to enhance understanding of gene-environment interactions in lung cancer etiology and translate observations into improved screening eligibility criteria.
Research reveals a link between Alzheimer's and lower lung cancer risk due to mitochondrial dysfunction and chronic inflammation. A study analyzing over 1000 patient samples identified altered genes and confirmed the protective effect of Alzheimer's against lung cancer.
Researchers developed an AI-based approach to extract lung nodules from chest CTs, improving diagnosis accuracy and reducing false positives. The method can be integrated into existing CADe systems and accommodate new data streams, potentially increasing the five-year survival rate for lung cancer patients.
A new study suggests that lung cancer screening programs targeting high-risk people could reduce costs while saving lives. The research found that focusing on high-risk individuals could reduce the number of people who need to be screened by over 80%, making the program more cost-effective.
Scientists have discovered a new type of immune cell that can predict which lung cancer patients will benefit from immunotherapy treatment. The study found that patients with high levels of tissue-resident memory T-cells in their tumour were more likely to survive, and the cells' behaviour played a key role in increasing survival rates.
Researchers discovered a mechanism that makes lung cancer cells dependent on mutated versions of the p53 gene, opening the potential for new treatments. They also showed that ChK1 inhibitors could effectively stop cancer cell multiplication in patients with gain of function p53 mutations.
Researchers have identified 18 new lung cancer susceptibility loci, including 10 novel ones, in the largest genome-wide association study to date. The study found variation around a subunit of the nicotinic receptor and genes related to telomere function play a significant role in adenocarcinoma risk.
The new clinical guideline provides evidence-based recommendations on the use of stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer. For medically inoperable patients with high-risk clinical scenarios, SBRT is recommended as an alternative to surgery or salvage therapy.
The ALEX trial demonstrates alectinib's superiority over crizotinib as first-line therapy for ALK-positive non-small cell lung cancer, with improved progression-free survival and brain metastasis outcomes. Alectinib achieved a 53% reduction in progression risk and 68.4% one-year progression-free rate compared to crizotinib.